160 related articles for article (PubMed ID: 16263257)
1. Innovation and greater probability of success in drug discovery and development -- from target to biomarkers.
Kola I; Hazuda D
Curr Opin Biotechnol; 2005 Dec; 16(6):644-6. PubMed ID: 16263257
[No Abstract] [Full Text] [Related]
2. Functional assays for screening GPCR targets.
Thomsen W; Frazer J; Unett D
Curr Opin Biotechnol; 2005 Dec; 16(6):655-65. PubMed ID: 16257523
[TBL] [Abstract][Full Text] [Related]
3. Exploiting naturally occurring DNA variation and molecular profiling data to dissect disease and drug response traits.
Schadt EE
Curr Opin Biotechnol; 2005 Dec; 16(6):647-54. PubMed ID: 16249078
[TBL] [Abstract][Full Text] [Related]
4. Cell-based assays in GPCR drug discovery.
Siehler S
Biotechnol J; 2008 Apr; 3(4):471-83. PubMed ID: 18383022
[TBL] [Abstract][Full Text] [Related]
5. Cell-based assays in GPCR drug discovery. In this issue.
Biotechnol J; 2008 Apr; 3(4):430. PubMed ID: 18412181
[No Abstract] [Full Text] [Related]
6. Editorial: Novel approaches to drug discovery in signal transduction.
Dekker L
Biotechnol J; 2008 Apr; 3(4):428-9. PubMed ID: 18412180
[No Abstract] [Full Text] [Related]
7. The evasive nature of drug efficacy: implications for drug discovery.
Galandrin S; Oligny-Longpré G; Bouvier M
Trends Pharmacol Sci; 2007 Aug; 28(8):423-30. PubMed ID: 17659355
[TBL] [Abstract][Full Text] [Related]
8. Label-free optical biosensor: a tool for G protein-coupled receptors pharmacology profiling and inverse agonists identification.
Lee PH
J Recept Signal Transduct Res; 2009; 29(3-4):146-53. PubMed ID: 19594401
[TBL] [Abstract][Full Text] [Related]
9. The application of cell-based label-free technology in drug discovery.
Xi B; Yu N; Wang X; Xu X; Abassi YA
Biotechnol J; 2008 Apr; 3(4):484-95. PubMed ID: 18412175
[TBL] [Abstract][Full Text] [Related]
10. Computational chemistry approaches to drug discovery in signal transduction.
Fischer PM
Biotechnol J; 2008 Apr; 3(4):452-70. PubMed ID: 18412174
[TBL] [Abstract][Full Text] [Related]
11. A modular approach for integrative analysis of large-scale gene-expression and drug-response data.
Kutalik Z; Beckmann JS; Bergmann S
Nat Biotechnol; 2008 May; 26(5):531-9. PubMed ID: 18464786
[TBL] [Abstract][Full Text] [Related]
12. Skin biopsies for the measurement of clinical pharmacodynamic biomarkers.
Phillips RL; Sachs AB
Curr Opin Biotechnol; 2005 Dec; 16(6):687-90. PubMed ID: 16257524
[TBL] [Abstract][Full Text] [Related]
13. Novel genomic methods for drug discovery and mechanism-based toxicological assessment.
Gant TW; Zhang SD; Taylor EL
Curr Opin Drug Discov Devel; 2009 Jan; 12(1):72-80. PubMed ID: 19152215
[TBL] [Abstract][Full Text] [Related]
14. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance.
Bosier B; Hermans E
Trends Pharmacol Sci; 2007 Aug; 28(8):438-46. PubMed ID: 17629964
[TBL] [Abstract][Full Text] [Related]
15. Metabolomics or metabolite profiles?
Villas-Bôas SG; Rasmussen S; Lane GA
Trends Biotechnol; 2005 Aug; 23(8):385-6. PubMed ID: 15939497
[No Abstract] [Full Text] [Related]
16. Cell signalling: making connections.
Gershon D
Nature; 2004 Nov; 432(7014):243-9. PubMed ID: 15538373
[No Abstract] [Full Text] [Related]
17. The 7 TM G-protein-coupled receptor target family.
Jacoby E; Bouhelal R; Gerspacher M; Seuwen K
ChemMedChem; 2006 Aug; 1(8):761-82. PubMed ID: 16902930
[TBL] [Abstract][Full Text] [Related]
18. The onset of a revolution in drug discovery.
Chatni MR
Trends Biotechnol; 2007 Apr; 25(4):142-4. PubMed ID: 17306391
[TBL] [Abstract][Full Text] [Related]
19. Functional genomics in antibacterial drug discovery.
Freiberg C; Brötz-Oesterhelt H
Drug Discov Today; 2005 Jul; 10(13):927-35. PubMed ID: 15993812
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics and biochemical profiling in drug discovery and development.
Watkins SM; German JB
Curr Opin Mol Ther; 2002 Jun; 4(3):224-8. PubMed ID: 12139307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
